4SC is a drug discovery
and development company that uses its cheminformatics-based technology
platform for the discovery and development of new drug candidates for
treatment of patients suffering from diseases with high medical needs.
4SC has been generating
a risk-balanced and continuously advancing pipeline of projects. 4SC's
therapeutic focus centres on cancer and inflammatory diseases as well
virus infections since these indications combine significant market
and high medical needs with reasonable development time and cost in the
early clinical stages.
first project on
the treatment of rheumatoid arthritis has completed clinical phase IIa.
Additional projects in research and pre-clinical stages are progressing
towards clinical development. All of 4SC's pipeline projects have been
generated by 4SC's proprietary technology platform.
aims to realise the
commercial potential of these programmes through licensing arrangements
with pharmaceutical partners.
combines the disciplines of chemistry and biology with the proprietary
virtual High Throughput Screening technology, 4SCanŽ. This technology
has transferred the principle of traditional High Throughput Screening
from the laboratory to the computer. The integration of this in silico
screening method into a seamless drug discovery and development
allows a significant reduction of development times from the
of active molecules through to proof-of-concept in clinical trials. The
cost and risk involved in bringing a drug to market are thus reduced.
company was founded
in 1997 and has its premises in Planegg-Martinsried, Germany. 4SC has
listed in the Prime Standard Segment (regulated market) of the
Stock Exchange since December 15, 2005.
4SC-202 is the
second epigenetic drug candidate currently in clinical development at
4SC. It is classified as a selective deacetylase (DAC) inhibitor, which
specifically inhibits the HDAC 1, 2 and 3 enzymes. 4SC-202 is an oral
anti-cancer compound and possesses a unique mode of action consisting
of both epigenetic regulation and cancer stem cell targeting.
Mode of action
4SC-202 is an
epigenetic compound targeting important signal transduction pathways
which play a key role in cancer development and progression.
modulates the Wnt signalling pathway, thus leading to an inhibition of
cellular signal transduction. The Wnt pathway plays a key role in
origination, metastasis, and recurrence of cancer diseases. 4SC-202
also inhibits the cancer stem cell properties and is thus a promising
therapeutic approach. The epigenetically modulated inhibition of the
Hedgehog signalling pathway underscores the inhibition of cancer stem
cells and further broadens the therapeutic scope of 4SC-202.
In terms of
its mode of action, this sharply differentiates 4SC-202 from
resminostat, 4SC’s most advanced epigenetic anti-cancer compound, and
its potential therapeutic applications. 4SC-202 is therefore an ideal
extension of and complement to 4SC's clinical pipeline. The compound
could be especially applied in the treatment of haematological cancers,
as well as cancers whose growth depends substantially on the Hedgehog
and Wnt signalling pathways.
which has already demonstrated good efficacy in preclinical models, is
currently being investigated in a clinical Phase I trial in patients
with haematological tumours. The compound has exhibited outstanding
tolerability in this trial to date. The anti-tumour activity derived
from its particular epigenetic mode of action makes 4SC-202 an
attractive future potential therapy for a broad range of cancer